After a banner year, Samsung will charge forward with 'super plant' plans, and look to expand abroad
Samsung Biologics’ future plans involve a lot of big, important, expensive buildings. And now, the company revealed in its Q4 earnings meeting, several of those expensive buildings, part of a massive “super plant,” will feature a heavy emphasis on mRNA, as the success and demand for Covid-19 vaccines continue to pay off.
Plant 5, the most recently announced building of its $2 billion “super plant,” will feature multi-modal mRNA, pDNA and viral vector product services, in addition to cell and gene therapies. That will be in addition to a vaccine drug substance manufacturing suite that’s expected to be ready to go at the already-erected facilities in Songdo within the “earlier part of this year,” Samsung said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.